Antitrust
More on Antitrust
Committee will investigate the rise and use of market power online and assess the adequacy of existing antitrust laws and current enforcement levels
Today, the House Judiciary Committee announced a bipartisan investigation into competition in digital markets. The investigation will include a series of hearings held by the Subcommittee on Antitrust, Commercial and Administrative Law on the rise of market power online, as well as requests for information that are relevant to the investigation.
Today, the House Judiciary Committee unanimously passed four bills to address prescription drug pricing, including H.R. 965, the CREATES Act; H.R. 2375, the Preserve Access to Affordable Generics and Biosimilars Act; H.R. 2374, the Stop STALLING Act; and H.R. 2376, the Prescription Pricing for the People Act of 2019. This markup is part of the first phase of the Committee's agenda to lower the soaring cost of prescription drugs.
Today, House Judiciary Committee Chairman Jerrold Nadler (D-NY) delivered the following opening statement for the markup of H.R. 2374, the Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics Act (Stop STALLING Act):
Today, House Judiciary Committee Chairman Jerrold Nadler (D-NY) delivered the following opening statement for the markup of H.R. 2376, the Prescription Pricing for the People Act of 2019:
"H.R. 2376, the 'Prescription Pricing for the People Act of 2019,' would require the Federal Trade Commission to conduct a comprehensive report on the state of competition in the drug supply chain.
Today, House Judiciary Committee Chairman Jerrold Nadler (D-NY) delivered the following opening statement for the markup of H.R. 965, the Creating and Restoring Equal Access to Equivalent Samples Act of 2019 (CREATES Act):
"H.R. 965, the 'Creating and Restoring Equal Access to Equivalent Samples Act of 2019,' or the 'CREATES Act,' is bipartisan legislation that would substantially lower drug prices by making it easier for generic pharmaceutical companies to obtain drug samples from branded companies, which they require in order to perform testing necessary to enter the market.
Today, House Judiciary Committee Chairman Jerrold Nadler (D-NY) delivered the following opening statement for the markup of H.R. 2375, the Preserve Access to Affordable Generics and Biosimilars Act:
"H.R. 2375, the 'Preserve Access to Affordable Generics and Biosimilars Act' is one of a series of bipartisan measures that we are considering today to address the critical need to lower the soaring cost of prescription drugs, which is jeopardizing the health and well-being of millions of Americans.
On April 30, 2019 at 2pm, the House Judiciary Committee will consider four bills to address prescription drug pricing, including H.R. 965, the CREATES Act; H.R. 2375, the Preserve Access to Affordable Generics and Biosimilars Act; H.R. 2374, the Stop STALLING Act; and H.R. 2376, the Prescription Pricing for the People Act of 2019.
Date: April 30, 2019
Time: 2:00 p.m.
Location: 2141 Rayburn House Office Building
Today, House Judiciary Committee Chairman Jerrold Nadler (D-NY) and Ranking Member Doug Collins (R-GA) introduced H.R. 2375, the bipartisan Preserve Access to Affordable Generics and Biosimilars Act. This legislation strengthens the Federal Trade Commission's (FTC) ability to challenge settlement agreements between large brand drug companies and generic drug companies in court, which will help lower prescription drug prices for Americans. The legislation will be marked up in the House Judiciary Committee on April 30, 2019.